Merck's pneumococcal vaccine wins US approval for high-risk children, teens
• The U.S. FDA has approved Merck's pneumococcal vaccine for expanded use in children and teenagers with chronic health conditions that increase their risk of infection. • This follows a June 2024 approval for adults and is based on a late-stage trial of 874 participants where the vaccine matched or outperformed the older PPSV23 version. • The approval is critical because pneumococcal disease can cause life-threatening conditions, including meningitis, pneumonia, and blood infections, particularly in high-risk youth.
reuters.com